Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.60 |
| ▸ | CTSK | P43235 | 4/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922943 | 1.00 | CTSS (0.60) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL7029037 | 1.00 | CTSS (0.60) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL30753714 | 0.87 | CTSS (0.60) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL4663069 | 0.87 | CTSS (0.57) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL4896150 | 0.87 | CTSS (0.60) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL17015 | 0.87 | CTSS (0.60) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL3997764 | 0.87 | CTSS (0.60) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL4664825 | 0.86 | CTSS (0.56) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL4664829 | 0.86 | CTSS (0.56) | CTSSCTSKPTPN1ATMSCN9A | |
| SCHEMBL12679226 | 0.85 | ATM (0.47) | CTSSCTSKPTPN1ATMSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
| EP-0873308-B1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS AND THEIR PHARMACEUTICALLY USEFUL SALTS | SK CORP (KR) | 2002-01-02 | — | — | EP | disclosed |
| EP-0820438-B1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | SK CORP (KR) | 2001-06-20 | — | — | EP | disclosed |
| US-6140532-A | O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same | SK CORPORATION (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0873308-A1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME | SK Corporation (KR) | 1998-10-28 | — | — | EP | disclosed |
| US-5756817-A | TREATMENT OF DISEASES OF CENTRAL NERVOUS SYSTEMS | YUKONG LIMITED (KR) | 1998-05-26 | — | — | US | disclosed |
| WO-1998015526-A1 | O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME | SK CORPORATION (KR) | 1998-04-16 | — | — | WO | disclosed |
| EP-0820438-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032375-A1 | O-CARBAMOYL-PHENYLALANINOL HAVING SUBSTITUENT AT BENZENE RING, ITS PHARMACEUTICALLY USEFUL SALTS AND METHOD FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CTSS 271/4885CTSK 124/4885PTPN1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.